Chris Shibutani
Stock Analyst at Goldman Sachs
(2.87)
# 1,589
Out of 5,117 analysts
96
Total ratings
54%
Success rate
6.57%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.97 | +112.90% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $3.48 | -13.79% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $14.65 | +2.39% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.49 | +12.32% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $94.52 | +44.94% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.30 | +54.93% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $507.16 | -40.45% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $39.22 | +30.04% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $207.63 | -25.35% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $12.33 | -67.56% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.18 | +178.55% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,077.75 | -32.92% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $18.31 | +42.00% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $145.26 | +5.33% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $229.98 | -24.78% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $44.49 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $54.64 | +26.28% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.80 | -34.34% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $80.75 | -71.52% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $9.26 | +439.96% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $81.32 | -36.06% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.09 | +139.14% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $10.41 | +72.91% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $8.67 | +96.08% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.57 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.74 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.16 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.97
Upside: +112.90%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $3.48
Upside: -13.79%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $14.65
Upside: +2.39%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.49
Upside: +12.32%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $94.52
Upside: +44.94%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.30
Upside: +54.93%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $507.16
Upside: -40.45%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $39.22
Upside: +30.04%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $207.63
Upside: -25.35%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $12.33
Upside: -67.56%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.18
Upside: +178.55%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,077.75
Upside: -32.92%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $18.31
Upside: +42.00%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $145.26
Upside: +5.33%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $229.98
Upside: -24.78%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $44.49
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $54.64
Upside: +26.28%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.80
Upside: -34.34%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $80.75
Upside: -71.52%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $9.26
Upside: +439.96%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $81.32
Upside: -36.06%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.09
Upside: +139.14%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $10.41
Upside: +72.91%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $8.67
Upside: +96.08%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.57
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.74
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.16
Upside: -